TGTX — TG Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $5.35bn
- $5.46bn
- $616.29m
Annual income statement for TG Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 6.69 | 2.79 | 234 | 329 | 616 |
| Cost of Revenue | |||||
| Gross Profit | 5.9 | 2.52 | 220 | 291 | 516 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 351 | 221 | 213 | 287 | 493 |
| Operating Profit | -345 | -218 | 20.6 | 41.9 | 123 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -348 | -224 | 13.1 | 25.6 | 107 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -348 | -224 | 12.7 | 23.4 | 447 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -348 | -224 | 12.7 | 23.4 | 447 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -348 | -224 | 12.7 | 23.4 | 447 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.63 | -1.65 | 0.085 | 0.172 | 2.77 |